[go: up one dir, main page]

PE20170640A1 - Derivados de quinolizinona como inhibidores de pi3k - Google Patents

Derivados de quinolizinona como inhibidores de pi3k

Info

Publication number
PE20170640A1
PE20170640A1 PE2016002810A PE2016002810A PE20170640A1 PE 20170640 A1 PE20170640 A1 PE 20170640A1 PE 2016002810 A PE2016002810 A PE 2016002810A PE 2016002810 A PE2016002810 A PE 2016002810A PE 20170640 A1 PE20170640 A1 PE 20170640A1
Authority
PE
Peru
Prior art keywords
amino
optionally substituted
pi3k inhibitors
quinolizinone
quinolizine
Prior art date
Application number
PE2016002810A
Other languages
English (en)
Inventor
Nirmal Kumar Jana
Sachin Jaysing Mahangare
Prashant Popatrao Vidhate
Dipak Lagad
Anand Jagannath Tarage
Sanjeev Anant Kulkarni
Venkata P Palle
Rajender Kumar Kamboj
Manojkumar Ramprasad Shukla
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53716533&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20170640(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PE20170640A1 publication Critical patent/PE20170640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se refiere a un compuesto de formula I, donde: R1 es 1H-pirazolo[3,4-d]pirimidin-4-amina, 9H-purin-6-amina, entre otros; R2 es hidrogeno, alquilo opcionalmente sustituido, entre otros; R3 es arilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, entre otros; R4 es halogeno sustituido, alquilo, entre otros; n es 0, 1 o 2. Son compuestos preferidos: 4-amino-6-((1-(7-fluoro-4-oxo-3-fenil-4H-quinolizina-2-il)etil)amino)-pirimidina-5-carbonitrilo; 2-(1-((2-amino-9H-purin-6-il)amino)etil)-7-fluoro-3-(3-fluorofenil)-4H-quinolizina-4-ona; entre otros. Tambien se refiere a una composicion farmaceutica y a un metodo de tratamiento. Dichos compuestos derivados de quinolizinona son inhibidores de PI3K, siendo utiles en el tratamiento de cancer, trastornos inflamatorios o trastornos autoinmunes
PE2016002810A 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k PE20170640A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2182MU2014 2014-07-04

Publications (1)

Publication Number Publication Date
PE20170640A1 true PE20170640A1 (es) 2017-05-26

Family

ID=53716533

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016002810A PE20170640A1 (es) 2014-07-04 2015-07-01 Derivados de quinolizinona como inhibidores de pi3k

Country Status (25)

Country Link
US (1) US9944639B2 (es)
EP (1) EP3164400A1 (es)
JP (1) JP6291601B2 (es)
KR (1) KR20170082490A (es)
CN (1) CN106470996B (es)
AP (1) AP2016009661A0 (es)
AU (1) AU2015283671B2 (es)
BR (1) BR112017000132A2 (es)
CA (1) CA2954231A1 (es)
CL (1) CL2017000006A1 (es)
CO (1) CO2017000011A2 (es)
CR (1) CR20160600A (es)
CU (1) CU24428B1 (es)
EA (1) EA201692557A1 (es)
GE (2) GEP20186934B (es)
HK (1) HK1232227A1 (es)
IL (1) IL249674B (es)
MA (1) MA40250A (es)
MX (1) MX2017000208A (es)
PE (1) PE20170640A1 (es)
PH (1) PH12017500007A1 (es)
SG (1) SG11201610770PA (es)
SV (1) SV2017005354A (es)
UA (1) UA115296C2 (es)
WO (1) WO2016001855A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207441B (zh) * 2014-11-01 2020-11-24 上海复尚慧创医药研究有限公司 蛋白激酶抑制剂
WO2017103825A1 (en) 2015-12-18 2017-06-22 Lupin Limited Quinolizinone derivatives as pi3k inhibitors
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
JP2021535907A (ja) * 2018-08-21 2021-12-23 南京明徳新薬研発有限公司 ピラゾロピリミジン誘導体及びそのｐｉ３ｋ抑制剤とする適用
CA3137213A1 (en) 2019-04-23 2020-10-29 Evotec International Gmbh Modulators of the integrated stress response pathway
WO2021164789A1 (zh) * 2020-02-21 2021-08-26 南京明德新药研发有限公司 一种吡唑并嘧啶类化合物的晶型及其应用
EP4149944A4 (en) * 2020-05-16 2024-07-03 Fochon Biosciences, Ltd. COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
MA63885B1 (fr) * 2021-08-09 2025-01-31 Scorpion Therapeutics, Inc. Composés inhibant l'isoforme alpha de pi3k et méthodes de traitement du cancer

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
NZ522076A (en) 2000-04-25 2005-08-26 Icos Corp Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
RS55551B1 (sr) 2004-05-13 2017-05-31 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
CA2730540A1 (en) 2004-05-13 2005-12-01 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CN101123968A (zh) 2004-06-04 2008-02-13 艾科斯有限公司 肥大细胞病的治疗方法
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
CA2909277A1 (en) 2006-04-04 2007-10-11 Kevan M. Shokat Kinase antagonists
CN101605797A (zh) 2006-11-13 2009-12-16 伊莱利利公司 治疗炎症疾病和癌症的噻吩并嘧啶酮
AU2008231384B2 (en) 2007-03-23 2011-09-15 Amgen Inc. Heterocyclic compounds and their use
US7705018B2 (en) 2007-03-23 2010-04-27 Amgen Inc. Substituted quinolines and their uses in treatment of inflammatory and related conditions
PL2137186T3 (pl) 2007-03-23 2016-09-30 Związki heterocykliczne i ich zastosowania
WO2009064802A2 (en) 2007-11-13 2009-05-22 Eli Lilly & Co. Inhibitors of human phosphatidyl-inositol 3-kinase delta
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2240451B1 (en) 2008-01-04 2017-08-09 Intellikine, LLC Isoquinolinone derivatives substituted with a purine useful as PI3K inhibitors
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CA2759724A1 (en) 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
SG176986A1 (en) 2009-06-25 2012-02-28 Amgen Inc Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CA2765817A1 (en) 2009-06-25 2010-12-29 Amgen Inc. 4h-pyrido[1,2-a]pyrimidin-4-one derivatives as pi3k inhibitors
AU2010265932B2 (en) 2009-06-25 2014-11-20 Amgen Inc. Heterocyclic compounds and their uses
CA2766100C (en) * 2009-06-29 2018-05-22 Incyte Corporation Pyrimidinones as pi3k inhibitors
CA2768843A1 (en) 2009-07-21 2011-01-27 Gilead Calistoga Llc Treatment of liver disorders with pi3k inhibitors
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
HUE035059T2 (hu) 2009-11-05 2018-05-02 Rhizen Pharmaceuticals S A Új benzopirán-kinát modulátorok
WO2011058112A1 (en) 2009-11-12 2011-05-19 Ucb Pharma S.A. Fused bicyclic pyrazole derivatives as kinase inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
JP2013514989A (ja) 2009-12-18 2013-05-02 アムジエン・インコーポレーテツド 複素環式化合物およびその使用法
UY33304A (es) 2010-04-02 2011-10-31 Amgen Inc Compuestos heterocíclicos y sus usos
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
US20110306622A1 (en) 2010-06-11 2011-12-15 Calitoga Pharmaceuticals, Inc. Methods of treating hematological disorders with quinazolinone compounds in selected subjects
EP2588473A1 (en) 2010-06-30 2013-05-08 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors
CA2803619A1 (en) 2010-06-30 2012-01-05 Amgen Inc. Heterocycle compounds and their uses
JP2013530236A (ja) 2010-07-01 2013-07-25 アムジエン・インコーポレーテツド Ｐｉ３ｋ活性の阻害剤としての複素環式化合物およびその用途
MX2012015135A (es) 2010-07-01 2013-05-06 Amgen Inc Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
AU2011272850A1 (en) 2010-07-02 2013-01-10 Amgen Inc. Heterocyclic compounds and their use as inhibitors of PI3K activity
JP2013540758A (ja) 2010-09-24 2013-11-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋ阻害化合物のアトロプ異性体
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
JP2013541591A (ja) 2010-11-04 2013-11-14 アムジエン・インコーポレーテツド 複素環化合物およびそれらの使用
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2011329806A1 (en) 2010-11-17 2013-05-30 Amgen Inc. Quinoline derivatives as PIK3 inhibitors
AU2011349669A1 (en) 2010-12-23 2013-07-11 Amgen Inc. Heterocyclic compounds and their uses
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
PH12013501855A1 (en) 2011-03-11 2018-03-21 Gilead Calistoga Llc Combination therapies for hematologic malignancies
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
UY34044A (es) * 2011-04-29 2012-11-30 Sanofi Sa Metodo de tratamiento contra el linfoma con inhibidores de piridopirimidinona de p13k/mtor
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
TW201306842A (zh) * 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
CN102838601A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 选择性磷酰肌醇3-激酶δ抑制剂
CN102838600A (zh) 2011-06-24 2012-12-26 山东亨利医药科技有限责任公司 苯基喹唑啉类PI3Kδ抑制剂
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
WO2013082540A1 (en) 2011-12-02 2013-06-06 Gilead Calistoga Llc Compositions and methods of treating a proliferative disease with a quinazolinone derivative
WO2013116562A1 (en) 2012-02-03 2013-08-08 Gilead Calistoga Llc Compositions and methods of treating a disease with (s)-4 amino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
CN104284679B (zh) 2012-03-13 2017-08-04 瑞斯比维特有限公司 药物制剂
PE20142457A1 (es) 2012-04-04 2015-02-07 Amgen Inc Compuestos heterociclicos y sus usos
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
SMT201900334T1 (it) 2012-07-04 2019-07-11 Rhizen Pharmaceuticals S A Inibitori selettivi di pi3k delta
WO2014015523A1 (en) 2012-07-27 2014-01-30 Hutchison Medipharma Limited Novel heteroaryl and heterocycle compounds, compositions and methods
WO2014023083A1 (zh) 2012-08-08 2014-02-13 山东亨利医药科技有限责任公司 PI3Kδ抑制剂
JP2015529195A (ja) 2012-08-14 2015-10-05 ギリアード カリストガ エルエルシー 癌を処置するための組合せ治療
HK1211027A1 (en) 2012-10-16 2016-05-13 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
US20140120060A1 (en) 2012-11-01 2014-05-01 Infinity Pharmaceuticals, Inc. Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
NZ708870A (en) 2012-12-21 2016-09-30 Gilead Calistoga Llc Isoquinolinone or quinazolinone phosphatidylinositol 3-kinase inhibitors
JP6125663B2 (ja) 2012-12-21 2017-05-10 ギリアード カリストガ エルエルシー ホスファチジルイノシトール３−キナーゼ阻害剤としての置換ピリミジンアミノアルキル−キナゾロン
WO2014106800A2 (en) 2013-01-04 2014-07-10 Aurigene Discovery Technologies Limited Substituted 2-amino pyrimidine derivatives as kinase inhibitors
UY35332A (es) 2013-02-15 2014-11-28 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
TW201522341A (zh) 2013-03-15 2015-06-16 Respivert Ltd 化合物
US9216985B2 (en) 2013-03-28 2015-12-22 Scifluor Life Sciences, Inc. 3-aryl-2-((arylamino)methyl)quinazolin-4-(3H)-ones
HK1223911A1 (zh) 2013-06-14 2017-08-11 Gilead Sciences, Inc. 磷脂醯肌醇3-激酶抑制剂
EA029614B1 (ru) 2013-07-02 2018-04-30 Ризен Фармасьютикалз Са Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма
CN104418849B (zh) 2013-09-02 2020-04-21 广东东阳光药业有限公司 取代的氨基嘧啶类化合物及其使用方法和用途
JP6494634B2 (ja) 2013-09-22 2019-04-03 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されているアミノピリミジン化合物および使用方法
SG11201607705XA (en) 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN105130966B (zh) 2014-05-07 2019-05-24 广东东阳光药业有限公司 炔基化合物及其使用方法和用途
WO2015175579A1 (en) 2014-05-15 2015-11-19 Calitor Sciences, Llc Alkynyl compounds and methods of use
WO2015191752A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
EA201692267A1 (ru) 2014-06-13 2017-06-30 Джилид Сайэнс, Инк. Ингибиторы фосфатидилинозитол-3-киназы
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015280138B2 (en) 2014-06-24 2018-06-14 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN107207441B (zh) * 2014-11-01 2020-11-24 上海复尚慧创医药研究有限公司 蛋白激酶抑制剂
CN105130984B (zh) 2015-09-23 2017-03-29 前湾医药科技（深圳）有限公司 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用

Also Published As

Publication number Publication date
SG11201610770PA (en) 2017-01-27
PH12017500007A1 (en) 2017-05-15
GEAP201814408A (en) 2018-08-27
CO2017000011A2 (es) 2017-04-10
EP3164400A1 (en) 2017-05-10
MA40250A (fr) 2017-05-10
JP2017519786A (ja) 2017-07-20
AP2016009661A0 (en) 2016-12-31
CL2017000006A1 (es) 2017-06-02
CN106470996B (zh) 2019-02-22
MX2017000208A (es) 2017-05-01
BR112017000132A2 (en) 2018-01-09
AU2015283671B2 (en) 2018-07-05
IL249674B (en) 2019-06-30
US9944639B2 (en) 2018-04-17
JP6291601B2 (ja) 2018-03-14
AU2015283671A1 (en) 2017-02-02
HK1232227A1 (zh) 2018-01-05
US20170137421A1 (en) 2017-05-18
IL249674A0 (en) 2017-02-28
KR20170082490A (ko) 2017-07-14
CN106470996A (zh) 2017-03-01
EA201692557A1 (ru) 2017-05-31
GEP20186934B (en) 2018-12-10
CA2954231A1 (en) 2016-01-07
CU24428B1 (es) 2019-06-04
CR20160600A (es) 2017-03-07
WO2016001855A1 (en) 2016-01-07
SV2017005354A (es) 2018-10-05
CU20160195A7 (es) 2017-05-10
UA115296C2 (uk) 2017-10-10

Similar Documents

Publication Publication Date Title
PE20170640A1 (es) Derivados de quinolizinona como inhibidores de pi3k
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
CY1123756T1 (el) Παραγωγα διπυραζολιου ως αναστολεις jak
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
CY1122266T1 (el) Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
PE20160689A1 (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 quinasas
MX374729B (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4.
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
PE20191245A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
PE20151064A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
NZ708864A (en) Substituted pyrimidine aminoalkyl-quinazolones as phosphatidylinositol 3-kinase inhibitors
PE20141974A1 (es) Compuestos de heterociclilo
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
CO6410298A2 (es) Pirimidinas fusionadas
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
PE20170936A1 (es) Compuestos novedosos de imidazopiridazina y su uso
MX382726B (es) Compuestos de hidroxil purinas y aplicaciones de estos
CO7160116A2 (es) Derivados de pirimidinona como agentes antimalaricos